HOME >> BIOLOGY >> NEWS
New hope for self-injury sufferers

Communication training, drug therapy combination greatly reduces or eliminates disorder

NASHVILLE, Tenn. - People who routinely injure themselves may do so in order to stimulate a release of feel-good chemicals in the brain, and most of those sufferers can now be helped with an innovative combination of two therapies, according to Travis Thompson, director of Vanderbilt University's John F. Kennedy Center for Research on Human Development.

Thompson is scheduled to present his findings on self-injury as the keynote speaker at the prestigious British Intellectual and Learning Disabilities (BILD) Conference in London Sept. 14.

Thompson and his colleagues have concluded that many of the estimated 50,000 to 300,000 Americans with developmental disabilities who injure themselves with acts such as head banging and self-biting do so either as a primitive form of communication or to stimulate the release of beta endorphins (the brain's natural "morphine") in the brain. Thompson's latest research indicates that sufferers can be helped dramatically by combining communication training with a regimen of the drug naltrexone, which blocks the brain's opiate receptors.

"This particular combination of therapies works because many people with severe disabilities self-injure either as a means of communicating basic needs or wants or because doing so releases beta endorphin," said Thompson, a professor of psychology, special education and psychiatry at Vanderbilt. "If you can provide an alternative form of communication that they understand, they will do that instead of self-injuring. And by combining two treatments - augmentative communication training and naltrexone - it appears we can greatly reduce or stop self-injury in most cases."

Naltrexone works by blocking the brain's opiate receptors, Thompson explained, so that when beta endorphin is released following self-
'"/>

Contact: Peggy Shaw
peggy.shaw@vanderbilt.edu
615-343-8557
Vanderbilt University
8-Sep-1999


Page: 1 2 3

Related biology news :

1. Sickle cell sufferers living longer, dying less from their disease
2. Physicists use fractals to help Parkinsons sufferers
3. Finding may help eczema sufferers tolerate smallpox vaccine
4. Hebrew University, German and British researchers develop means to help stress sufferers
5. Xyzal shows significant improvements in quality of life for persistent allergic rhinitis sufferers
6. Potential allergy vaccine boosts hope for sufferers
7. Heroin users mystery a hope for back pain sufferers
8. Doctors failure to reevaluate asthma severity hurts wheezing sufferers
9. New hope for neurodegenerative disease sufferers
10. Study points to positive results from vitamin D supplements for MS sufferers
11. Human trials of new vaccine technique prove promising for allergy sufferers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: